Slide 1: Second Quarter 2014 Earnings Presentation
Exhibit 1 Second Quarter 2014 Earnings Presentation August 6, 2014
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u
Slide 3: Pipeline
LEAD DEVELOPMENT PROGRAMS AML ‘Stem cell mobilization CML BL-7010 Celiac disease ADDITIONAL DEVELOPMENT PROGRAMS BL-5010 ‘Skin lesions Inflammatory bowel disease BL-9010 Severe asthma/allergies BL-1110 Neuropathic pain/scleroderma PROGRAMS PARTNERED OR IN CO-DEVELOPMENT BL-1040 Ventricular remodelin
Slide 4: Update on Operations and Lead Programs
Chief Executive Officer Kinneret Savitsky, Ph.D. Update on Operations and Lead Programs 4
Slide 5: BL-1040: First-in-class bioabsorbable cardiac matrix for prevention of ventricular remodeling
BL-1040: FIRST-IN-CLASS BIOABSORABLE CARDIAC MATRIX FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI • Pivotal CE Mark registration trial continues on schedule – Trial enrolled >200 patients of ~300 patients – Endpoints: End diastolic volume index, QLQ, six-minute walk test • Expect to complet
Slide 6: BL-8040: Best-in-class CXCR4 antagonist
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST Promising Platform Candidate for Hematological Cancers ü Evidence for robust apoptosis of cancer cells; Substantial mobilization of cancer cells ü Strong global IP estate: 13 issued/25 patents pending worldwide (two recent issued in U.S) ü Received orphan drug
Slide 7: BL-8040: Continued
BL-8040: CONTINUED Stem cell mobilization üJun. 2014: Received approval from Israeli Ministry of Health to begin human studies – Within 4-6 weeks: Initiate two-part Phase 1 study Part 1: Safety and tolerability as a standalone therapy • Dose escalation (randomized, double-blind, placebo-controlled);
Slide 8: BL-7010: Novel gliadin binding polymer for celiac disease
BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE Exciting progress in a fast-growing market – Significantly increased Pharma interest – Very high-need and underserved population Phase 1/2 study ongoing in celiac patients: ü Mar. 2014: Completed dose escalation stage; initiated repeated-dose
Slide 9: Second Quarter 2014 Financial Overview
Chief Financial & Operating Officer Philip A. Serlin, CPA, MBA Second Quarter 2014 Financial Overview 9
Slide 10: Corporate Highlights
Corporate Highlights • Strong current cash position: $33.1 million at June 30, 2014 • Funds operational capital through end of 2016 • Expect to reach several value inflection points during this time • Broad U.S. institutional investor base • U.S. investors now hold roughly 2/3 of total shares outsta
Slide 11: Financial Overview
Financial Overview (in USD at 30-Jun-14 exchange rate) • Research and development • Total R&D expenses decreased by $5.3 million, to $5.6 million for the six months ended June 30, 2014 • Primarily from termination of the BL-1020 CLARITY clinical trial in March 2013, as well as certain one-time costs
Slide 12: Financial Overview
Financial Overview (in USD at 31-Mar-14 exchange rate) • General and administrative • G&A expenses decreased by $0.2 million, to $1.9 million for the six months ended June 30, 2014 • Primarily due to a one-time expense for professional services in the 2013 period • Non-operating income • Non-operati
Slide 13: Major Milestones over next 12 Months
Major Milestones over next 12 Months BL-7010 (Celiac Disease) phase 1/2 completion BL-8040 (SC Mobilization) phase 1 initiation BL-8040 (AML) phase 2 partial results* BL-8040 (CML) phase 1/2 study initiation BL-1040 (AMI) complete CE mark study enrollment BL-7010 (Celiac Disease) CE pivotal study in
Slide 14: Thank You! Questions?
Bench Bedside do Patiner *& = ae a THANK YOU! QUESTIONS? BIOLINEM ><